Compare BTGO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BTGO | ANL |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.3M | 611.1M |
| IPO Year | 2025 | 2022 |
| Metric | BTGO | ANL |
|---|---|---|
| Price | $5.27 | $13.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $14.83 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 994.7K | 200.8K |
| Earning Date | 05-13-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | $34.41 | N/A |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.67 | $0.88 |
| 52 Week High | $15.30 | $17.25 |
| Indicator | BTGO | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 54.83 |
| Support Level | $4.71 | $12.41 |
| Resistance Level | $5.72 | $13.29 |
| Average True Range (ATR) | 0.31 | 1.04 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 72.24 | 43.57 |
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.